The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
|Articles|June 18, 2006
- Applied Clinical Trials-06-19-2006
- Volume 0
- Issue 0
BBK Healthcare, Inc. Evolves to Become BBK Worldwide
BBK Adds Global Alliances and Restructures Offerings to Advance Patient Recruitment.
Advertisement
BOSTON-BBK Healthcare, Inc., a leading patient recruitment company for the clinical R&D segment of the pharmaceutical, biotechnology, and medical device industries announces the evolution of its global capabilities and presence to become BBK Worldwide. The company is leveraging its 20-year industry experience in patient recruitment planning and implementation in North America with wider global coverage and a strategic restructuring of offerings to respond to the increasingly complex needs of clinical research sponsors entering new and emerging global markets.
BBK Worldwide's official launch coincides with the Drug Information Association (DIA) Annual Meeting in Philadelphia from June 18–22, where BBK will convene global alliance members for an inaugural summit meeting prior to the DIA conference.
Geographic expansion includes BBK Worldwide offices in London and Prague, and the addition of the BBK Worldwide Alliance, a network of select, best-in-class companies with capabilities in more than 75 countries.
Articles in this issue
Advertisement
Related to this article
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
3
Where AI Governance in Clinical Development Falls Short
4
Syneos Health, Optum Partner on Adaptive Clinical Development Model
5